Sen-Jam Pharmaceutical Advances First-in-Class FDA Hangover Prevention Therapy, SJP-001, to Phase 2 Trials in Canada

Cliantha Research spearheads clinical study as growing evidence and investor enthusiasm converge around inflammation-based innovation.

HUNTINGTON, N.Y., July 25, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical has initiated a Phase 2 clinical trial for its pioneering hangover prevention therapy, SJP-001, now underway in Canada with global research partner Cliantha. This milestone positions SJP-001 to become the first FDA therapy to directly target the inflammatory root cause of alcohol-induced symptoms—moving beyond surface-level relief like hydration. It also represents a flagship validation of Sen-Jam's PAIR Technology (Preemptive Anti-Inflammatory Regulators) platform—a scalable, modular technology designed to unlock next-generation broad spectrum anti-inflammatory therapies for a wide range of inflammation-driven conditions with massive unmet needs.

Amid increasing global scrutiny of alcohol's long-term health risks, SJP-001 arrives at a pivotal moment. In January 2025, the U.S. Surgeon General issued a stark warning linking chronic alcohol consumption to increased cancer risk, citing systemic inflammation as a major driver—a warning that echoes the scientific foundation of Sen-Jam's therapeutic approach. 

"We're not only addressing the acute discomfort of the morning after," said Jackie Iversen, RPh, MS, Co-Founder and Chief Clinical Officer at Sen-Jam. "We're contributing to the global response to alcohol-related inflammation and long-term health implications."

"At Desire Ventures, we back companies that combine purpose and performance. Supporting a Canadian-led clinical program with worldwide implications makes Sen-Jam a natural fit," said Assad S. Aslam, Managing Partner of Desire Ventures, an investor in the program.

Sen-Jam's peer-reviewed publication from January 2025 further elaborates on this connection, reinforcing the need for innovation specifically targeting inflammatory responses:
  Read: Alcohol Use, Inflammation, and Cancer Risk

Inflammation is the Mechanism. SJP-001 is the Solution. And the Market is Ripe for a Leader.

SJP-001 is protected by 23 global patents and built on a novel combination of repurposed drugs designed to safely disrupt the inflammatory cascade triggered by alcohol consumption. Unlike surface-level remedies, SJP-001 targets the biological driver of hangover symptoms—offering a scientifically grounded, first-in-class approach.

A published pilot study has already shown significant reductions in both the severity and duration of symptoms, confirming the compound's early efficacy:
  Pilot Study of SJP-001 – PubMed

Further reinforcing this approach, Dr. Joris Verster—widely regarded as the father of alcohol hangover research—has recently published a comprehensive review of existing remedies underscoring the importance of inflammation-targeted interventions. His analysis validates anti-inflammatory mechanisms as the most promising route for future therapies:
  Verster 2024 Review – Journal of Translational Medicine

"Our innovation is about more than relief—it's about resilience, well-being, and protecting people who choose to consume alcohol socially," continued Iversen. "According to the World Health Organization, that's approximately 2.4 billion people globally."

And the global market is finally catching up to science. Grand View Research projects the hangover remedies market will grow at a 14.9% CAGR, reaching $6.2 billion by 2030—a category long dismissed as folklore now emerging as a credible, clinical frontier.

A Movement in Motion: Sen-Jam's Community-Powered Model Attracts 1,100+ Investors Backing the Future of Preventive Pharma

The tides are turning in healthcare. As consumers demand more control over their well-being, and investors seek meaningful exposure to preventive, protective, and more elegant inflammation-targeted therapies, Sen-Jam is answering the call—with science, structure, and choice.

To give mission-aligned supporters maximum flexibility, Sen-Jam is offering three complementary ways to participate:

• Philanthropic Giving via CataCap
• Community Investing via Wefunder
• Reg D 506C - Contact Sen-Jam Directly

"We're democratizing access to a market traditionally closed off to all but the largest players," said Jim Iversen, CEO. "This is about more than raising capital. It's about building a values-aligned community that's invested in the future of health and in helping each other live healthier, longer lives."

Sen-Jam has already attracted over 1,100 investors, with about 30% choosing to invest a second time—a signal of trust, traction, and shared belief in the company's mission and model. If you're interested in exploring their fundraising campaign, visit their Wefunder offer.

Interested parties are also invited to join Sen-Jam's leadership for an exclusive deep dive into SJP-001's market potential, the science behind it, and how you can participate in the journey. Next Wednesday, July 30th at 1pm EST. Registration for this event is required and can be secured here.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is a drug innovation company developing safe and efficacious therapies for some of the world's most widespread and costly health challenges. By repurposing well-characterized small molecules through its proprietary delivery platform—and leveraging the FDA's accelerated 505(b)(2) regulatory pathway—Sen-Jam is building a new class of anti-inflammatories designed to target the entire spectrum of inflammatory pathways, not just one or two like traditional blockbusters. This platform approach opens doors to faster clinical validation, broader indications, and therapies that are not only effective—but accessible, safe, and scalable. Investor information available at Wefunder. Learn more at www.sen-jam.com.

CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
[email protected]
781-913-1902

SOURCE Sen-Jam Pharmaceutical